Why the study?
Does continued warfarin treatment reduce the incidence of clinically significant device-pocket hematoma in patients undergoing pacemaker or ICD surgery compared to bridging therapy with heparin?
Does continued warfarin treatment reduce the incidence of clinically significant device-pocket hematoma in patients undergoing pacemaker or ICD surgery compared to bridging therapy with heparin?
Continuing warfarin during pacemaker or ICD surgery significantly reduces the risk of device-pocket hematoma compared to heparin bridging.
No takes yet. Share an insight, caveat, or question.
Supports continued warfarin without bridging in device implantation; challenges routine heparin use in guidelines.
Birnie et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: